MASSACHUSETTS GENERAL HOSPITAL
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
2.5k
Trial Phases
6 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2072 trials with phase data)β’ Click on a phase to view related trials
The PREGNANT (Pregnant Resident Empowerment, GuidaNce, and Advocacy iN Training) Coaching Project
- Conditions
- Burnout, ProfessionalWell-Being, PsychologicalImposter PhenomenonSelf EfficacyQuality of Life
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT07221422
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈBrigham Women's Hospital, Boston, Massachusetts, United States
Behavioral Health Program for Short-Stay Nursing Facility Residents & Care Partners
- Conditions
- Nursing Home ResidentSkilled Nursing FacilityDepressionFeasibility StudiesCaregiver
- First Posted Date
- 2025-10-24
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07220486
Pilot Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
- Conditions
- Lynch SyndromeCrohn DiseaseInflammatory Bowel DiseasesHealthy
- First Posted Date
- 2025-10-22
- Last Posted Date
- 2025-10-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07219537
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
The Effect of Thalamic Stimulation on Sleep Oscillations
- Conditions
- SleepNeuromodulation
- First Posted Date
- 2025-10-15
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT07217080
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerging Adults
- Conditions
- Alcohol Use Disorder
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07214831
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 493
- Next
News
Tonix Pharmaceuticals Initiates First-in-Human Study of Intranasal Oxytocin for Rare Endocrine Disorder
Tonix Pharmaceuticals has dosed the first patient in the FOCUS study, evaluating intranasal potentiated oxytocin products TNX-1900 and TNX-2900 for arginine-vasopressin deficiency (AVP-D), a rare endocrine disorder formerly known as central diabetes insipidus.
Researchers Plan FDA Application for Groundbreaking CRISPR Base Editing Trial Following Baby KJ's Successful Treatment
Doctors plan to request FDA approval this winter for a clinical trial testing CRISPR base editing in seven different urea cycle disorders, following the successful treatment of baby KJ with CPS1 deficiency.
Sonoma Biotherapeutics Reports Promising Phase 1 Results for CAR-Treg Therapy in Refractory Rheumatoid Arthritis
Sonoma Biotherapeutics announced positive interim results from its Phase 1 REGULATE-RA trial of SBT-77-7101, showing a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome in refractory rheumatoid arthritis patients.
Tonix Pharmaceuticals Advances TNX-1500 Anti-CD40L Antibody for Transplant Rejection Prevention
Tonix Pharmaceuticals presented Phase 1 safety and biomarker data for TNX-1500, a third-generation Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection.
Wearable Heart Rate Variability Patch Reduces Substance Use by 64% in Recovery Patients
Mass General Brigham researchers demonstrated that a wearable heart rate variability biofeedback device significantly reduced substance cravings and use in early recovery patients.
SELLAS Life Sciences Announces R&D Day to Showcase Phase 3 AML Trial Results and CDK9 Inhibitor Program
SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.
Biodegradable Brain Implants Show Promise in Preventing Glioblastoma Recurrence Through Immune System Reprogramming
Researchers at Massachusetts General Hospital have developed a biodegradable wafer implant called CANDI that reprograms immune cells to fight glioblastoma recurrence after surgical removal.
Aicuris Reports Positive Phase 2 Results for Pritelivir in Refractory HSV Infections and Favorable Phase 1 Safety Data for AIC468
Pritelivir demonstrated superior lesion healing rates compared to foscarnet in Phase 2 trial, with 93% vs. 57% of patients achieving healing within 28 days of treatment.
FDA Clears Clinical Trial for Pig Kidney Transplants as Second Patient Achieves Dialysis-Free Life
Bill Stewart, a 54-year-old New Hampshire man, successfully received a genetically engineered pig kidney transplant on June 14 and no longer requires dialysis after being discharged from Massachusetts General Hospital.
Treeline Biosciences Initiates Three Phase 1 Trials Targeting BCL6, KRAS, and EZH2 with $1.1B in Total Funding
Treeline Biosciences has launched Phase 1 clinical trials for three oncology programs: TLN-121 (BCL6 degrader), TLN-372 (pan-KRAS inhibitor), and TLN-254 (EZH2 inhibitor) targeting lymphomas and solid tumors.